Monday, March 6, 2017

Hepatitis C treatments - Trio will present rates of treatment denials; Medicare, Medicaid and private insurers

MARCH 9, 2017
Coverage Denials Eyed in HCV Rx Nonstarts
By Gina Shaw
Coverage denials by payors are the main factor in a dramatic rise in failure to start hepatitis C drug treatment over the past three years, according to new data released March 8 by Trio Health, which has collected real-world evidence on 15,000 HCV patients since the launch of the direct-acting antiviral agents (DAAs) in 2014.

Trio Health to Present Data Showing Patient Demand for Curative Hepatitis C Therapies Including Denial Rates by Payer Type

Interim findings from 15,000-patient study to be reviewed on webcast on March 8, 2017

LA JOLLA, CA--(Marketwired - March 06, 2017) - Trio Health today announced it will unveil interim results from its study evaluating real-world demand for curative hepatitis C treatments. Using its first-of-a-kind platform designed to track drug prescriptions, starts and denials in real time -- from a doctor's prescription to the pharmacy to payers -- Trio will present rates of treatment denials based on payer type, including Medicare, Medicaid and private insurers. The study includes over 15,000 patients nationwide.

The data will be presented at a meeting in New York City organized by The Trout Group and webcast beginning at 12:15 p.m. EST on March 8, 2017. To hear the webcast, please go to at

About Trio Health
Trio Health's mission is to improve the quality of care in patient outcomes through coordinating the efforts of all patient care stakeholders. Their first-of-its-kind Innervation platform tracks patients throughout the course of their treatment, giving pharmaceutical/biotechnology companies, specialty pharmacies and physicians access to information and opportunities that simply don't exist anywhere else. Learn more at

No comments:

Post a Comment